FMR1 and Parkinson disease: In conclusion, our results based on the genome‐wide study and assessment of a clinical status are suggestive of modifying effects of genetic risk loci linked to PD, on the risk of neurological involvement in FMR1‐CGG small expansion carriers, resulting in a wide spectrum and severity of FXTAS‐like symptoms.